» Articles » PMID: 22265971

MicroRNA-195-5p Suppresses Glucose Uptake and Proliferation of Human Bladder Cancer T24 Cells by Regulating GLUT3 Expression

Overview
Journal FEBS Lett
Specialty Biochemistry
Date 2012 Jan 24
PMID 22265971
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

It has been reported that expression of glucose transporter member 3 (GLUT3) is up-regulated in bladder cancers. However, the regulating mechanism remains unknown. Here, we assessed whether microRNAs (miRNAs) regulate GLUT3 expression in bladder cancers. In our study, miR-195-5p was identified to directly targeted GLUT3 3'-untranslated region (UTR) in bladder cancer T24 cells. Small interfering RNA (siRNA)- and miR-195-5p-mediated GLUT3 knockdown experiments revealed that miR-195-5p decreased T24 cells glucose uptake, inhibited cell growth and promoted cell apoptosis through suppression of GLUT3 expression. Therefore, miR-195-5p is a novel and also the first identified miRNA that targets GLUT3, and the aberrant decreased expression of miR-195-5p and consequent GLUT3 up-regulation may contribute to bladder carcinogenesis.

Citing Articles

Linking microRNA to metabolic reprogramming and gut microbiota in the pathogenesis of colorectal cancer (Review).

Bin Wan Mohd Nor W, Kwong S, Fuzi A, Said N, Jamil A, Lee Y Int J Mol Med. 2025; 55(3).

PMID: 39820715 PMC: 11759585. DOI: 10.3892/ijmm.2025.5487.


Deciphering the multifaceted role of microRNAs in hepatocellular carcinoma: Integrating literature review and bioinformatics analysis for therapeutic insights.

Rahdan F, Saberi A, Saraygord-Afshari N, Hadizadeh M, Fayeghi T, Ghanbari E Heliyon. 2024; 10(20):e39489.

PMID: 39498055 PMC: 11532857. DOI: 10.1016/j.heliyon.2024.e39489.


Envisioning Glucose Transporters (GLUTs and SGLTs) as Novel Intervention against Cancer: Drug Discovery Perspective and Targeting Approach.

Shafi S, Ahmed Khan M, Ahmad J, Rabbani S, Singh S, Najmi A Curr Drug Targets. 2024; 26(2):109-131.

PMID: 39377414 DOI: 10.2174/0113894501335877240926101134.


Transcriptional regulation and post-translational modifications in the glycolytic pathway for targeted cancer therapy.

Ni X, Lu C, Xu G, Ma J Acta Pharmacol Sin. 2024; 45(8):1533-1555.

PMID: 38622288 PMC: 11272797. DOI: 10.1038/s41401-024-01264-1.


Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment.

Hu B, Zhang X, Zhu S, Wang C, Deng Z, Wang T Eur J Med Res. 2024; 29(1):92.

PMID: 38297388 PMC: 10829481. DOI: 10.1186/s40001-024-01672-3.